Increasing complexity of novel drugs and cost constraints have encouraged medicines administration to be shifted away from their traditional setting of a hospital or clinic to more cost-effective alternatives such as the patient’s own home. The ability for patients to self-administer life-changing molecules that treat chronic diseases such as rheumatoid arthritis and multiple sclerosis, among others, is just one of the benefits of wearable injector.

In this interview with Andrei Josef, chief executive officer of Sorrel Medical, an Eitan Group company, we explore the latest trends in the fast growing and highly innovative world of wearable drug delivery systems from the perspective of a developer.